<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="35457">Angiotensin-converting enzyme inhibitors</z:chebi> (ACEI's) are an important medication in the treatment of <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, ACEIs may cause harmful side effects, such as the <z:e sem="disease" ids="C0021141" disease_type="Disease or Syndrome" abbrv="SIADH">syndrome of inappropriate secretion of antidiuretic hormone</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SIADH</z:e>), which is a rare but important side effect </plain></SENT>
<SENT sid="2" pm="."><plain>We describe here a case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SIADH</z:e> associated with ACEI administration in a 6-year-old boy with <z:hpo ids='HP_0001723'>restrictive cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>After recovery from <z:hpo ids='HP_0011009'>acute</z:hpo> exacerbation of <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> by tolvaptan administration, an ACEI (cilazapril) was started to decrease the production of <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi>, which upregulates serum antidiuretic hormone secretion </plain></SENT>
<SENT sid="4" pm="."><plain>The patient's <z:hpo ids='HP_0001635'>heart failure</z:hpo> symptoms worsened, including accumulation of right <z:hpo ids='HP_0002202'>pleural effusion</z:hpo> and <z:hpo ids='HP_0001541'>ascites</z:hpo>, after the initiation of ACEI administration </plain></SENT>
<SENT sid="5" pm="."><plain>Cessation of ACEI administration dramatically improved his symptoms </plain></SENT>
<SENT sid="6" pm="."><plain>Because it is difficult to distinguish <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SIADH</z:e> associated with ACEI from worsening <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo>, the possibility of fluid retention due to ACEI administration should always be considered when this agent is administered to patients with <z:hpo ids='HP_0001635'>heart failure</z:hpo> </plain></SENT>
</text></document>